Using Large Diabetes Databases for Research by Wild, Sarah et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using Large Diabetes Databases for Research
Citation for published version:
Wild, S, Fischbacher, C, McKnight, J & (on Behalf of the Scottish Diabetes Research Network Epidemiology
Group) 2016, 'Using Large Diabetes Databases for Research' Journal of Diabetes Science and Technology.
DOI: 10.1177/1932296816645120
Digital Object Identifier (DOI):
10.1177/1932296816645120
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Diabetes Science and Technology
Publisher Rights Statement:
© 2016 Diabetes Technology Society
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Journal of Diabetes Science and Technology
2016, Vol. 10(5) 1073 –1078
© 2016 Diabetes Technology Society
Reprints and permissions: 
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1932296816645120
dst.sagepub.com
Special Section
Large diabetes databases with substantial population cover-
age can be generated from a variety of sources. These include 
directly from data collected as part of routine clinical care, 
data collected for quality registers, administrative data such 
as population estimates and death registrations, and research 
studies using both observational and trial designs. Each 
approach has advantages and disadvantages and understand-
ing the limitations is essential for interpreting findings from 
research using different types of information. For example, 
although trial data are likely to represent the best quality data 
for assessing effectiveness of an intervention in terms of 
internal consistency, completeness and accuracy they are 
likely to be derived from a subgroup of the population that 
might therefore introduce bias and sample sizes are fre-
quently too small to study rare outcomes. In contrast data 
collated from sources not designed primarily for research 
including clinical records, quality registers, and administra-
tive data may be quicker and cheaper to obtain than trial data 
in settings where such systems are well established. These 
frequently include larger, more representative populations 
than trial-based databases and are at less risk of recall and 
observer bias that may develop from knowledge of research 
questions among trial participants and staff. However these 
“secondary-use” databases are likely to include poorer qual-
ity data, frequently with missing or limited data on important 
potential confounding factors and findings from their analy-
sis therefore need to be interpreted appropriately.
The focus of this review is on the use of databases derived 
from clinical records, quality registers and administrative data 
and covers some of the key issues in use and interpretation of 
these data. The recent publication of the REporting of studies 
Conducted using Observational Routinely-collected health 
Data (RECORD) Statement1 will encourage authors to be 
more explicit in describing their approach to using such data.
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Abstract
There are an increasing number of clinical, administrative and trial databases that can be used for research. These are particularly 
valuable if there are opportunities for linkage to other databases. This paper describes examples of the use of large diabetes 
databases for research. It reviews the advantages and disadvantages of using large diabetes databases for research and suggests 
solutions for some challenges. Large, high-quality databases offer potential sources of information for research at relatively low 
cost. Fundamental issues for using databases for research are the completeness of capture of cases within the population and time 
period of interest and accuracy of the diagnosis of diabetes and outcomes of interest. The extent to which people included in the 
database are representative should be considered if the database is not population based and there is the intention to extrapolate 
findings to the wider diabetes population. Information on key variables such as date of diagnosis or duration of diabetes may 
not be available at all, may be inaccurate or may contain a large amount of missing data. Information on key confounding factors 
is rarely available for the nondiabetic or general population limiting comparisons with the population of people with diabetes. 
However comparisons that allow for differences in distribution of important demographic factors may be feasible using data 
for the whole population or a matched cohort study design. In summary, diabetes databases can be used to address important 
research questions. Understanding the strengths and limitations of this approach is crucial to interpret the findings appropriately.
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Outline of the Review
This review describes the Scottish approach, as described 
previously in detail,2 to collecting data on almost the whole 
population of people with diagnosed diabetes in Scotland 
and for secondary use of the data for research and compares 
and contrasts the approaches used for other databases. In 
brief, the current Scottish Care Information (SCI)–Diabetes 
system has been developed over many years by clinical and 
technical experts to support clinical care, building on an 
agreed set of consistent definitions to define a core data set. 
SCI-diabetes has expanded over time to include call and 
recall for diabetic retinopathy screening and assessment of 
foot risk.
Relevant information is entered by clinical staff respon-
sible for diabetes management in primary and secondary care 
as part of the process of care. They also gain access to infor-
mation relevant to diabetes care entered by other health pro-
fessionals. An annual summary of the data in the system is 
provided in the Scottish Diabetes Survey.3 Patients have 
access to their records through the My Diabetes My Way 
patient portal.4 Following approval from a national ethics 
committee and from the Public Benefit and Privacy Panel (a 
body that reviews the use of data for research for which con-
sent has not been obtained from every individual), deidenti-
fied data are made available to researchers who have received 
approved data governance training. Key aspects of using the 
SCI-Diabetes database for research are considered below, 
with comparison to approaches used in other diabetes data-
bases. Advantages and disadvantages of using large data-
bases for research are summarized in Table 1.
Important Components of a Database
Diagnosis of Diabetes
Clearly the key entry criterion for a diabetes database should 
be a valid diagnosis of diabetes. This can however be chal-
lenging to establish. International bodies provide diagnostic 
criteria that change over time5,6 and are unlikely to be applied 
uniformly in clinical practice. Few databases provide infor-
mation on the criteria used to make a diagnosis. Several qual-
ity improvement registers such as the Swedish Diabetes 
Register and the databases that contribute to the Joint Asia 
Diabetes Evaluation (JADE) registry are predominantly 
based on registration of people with diagnosed diabetes by 
clinical staff.7,8 Electronic medical records of patients attend-
ing 1 or more centers such as those collated by Dr Mohan’s 
Diabetes Specialities Centres in southern India provide a 
resource for clinical care and for research.9 The Cardiovascular 
Risk Reduction in South Asia Translation Trial is based on 
people with a diagnosis of diabetes on the basis of the 1999 
World Health Organization criteria and data from partici-
pants have been used to produce several research papers 
beyond the original trial.10
The Scottish diabetes register derived from SCI-Diabetes 
is populated on the basis of diagnoses made in primary and 
secondary care using fasting (and, less commonly, postchal-
lenge) glucose levels and random HbA1c values and the sub-
sequent data entry and use of relevant disease codes in 
primary care databases and data entry into electronic clinical 
records after a hospital outpatient/ambulatory care visit. It is 
possible for SCI-Diabetes to feed relevant information col-
lected in other settings into primary care databases. This is 
extremely helpful for audit and for providing information for 
the pay-for-performance scheme, the Quality Outcomes 
Framework, introduced into UK general practice in 2004. 
Daily linkage to the Community Health Index master patient 
index provides frequent updating of dates of registration and 
deregistration with Scottish general practice as well as dates 
of death. The SCI-diabetes database is validated in clinical 
practice using responses to annual invitations to diabetic reti-
nopathy screening. For example, in 2010 191 571 individu-
als were invited for screening of whom 2% were suspended 
from the screening program and diabetes register because the 
person was subsequently found not to have diabetes.11
Extracts from the clinical database that have been deiden-
tified for use in research have been validated against hospital 
admissions mentioning diabetes12 or against sulphonylurea 
prescriptions (unpublished data) and this work suggests that 
over 99% of people with diagnosed diabetes in Scotland are 
included in both clinical and research databases. As a conse-
quence misclassification bias of diagnosed diabetes is not 
likely to be a major problem. As type 2 diabetes may be 
asymptomatic there are likely to be people with undiagnosed 
diabetes who are not included in the SCI-diabetes database. 
The most recent estimates, derived from estimates of preva-
lence of both diagnosed and undiagnosed diabetes from 
models using screening data compared to estimates of preva-
lence of diagnosed diabetes, suggest that approximately 15% 
of diabetes may be undiagnosed in Scotland.13
Other diabetes databases use different approaches to vali-
dation of diagnosis of diabetes. For example, the case defini-
tion used by QRESEARCH in a database derived from 240 
UK primary care practices and 4 million patients is based on 
Table 1. Advantages and Disadvantages of Using Large 
Databases for Research.
Advantages Disadvantages
Relatively quick and cheap to 
use compared to primary data 
collection once set up
Representative if population based
Further potential from linkage 
to other databases and for 
comparisons to other databases 
if definitions are harmonized
Large numbers improve power for 
studying rare outcomes
Effort and expense required 
to set up and maintain
Data governance issues must 
be addressed
Completeness and accuracy 
must be described
May lack key variables
Potential for bias
Statistically significant 
differences may not be 
clinically significant
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the presence of a specific disease code or more than 2 pre-
scriptions for drugs used to treat diabetes (insulin or oral 
agents).14 The Danish Diabetes Register is also based on a 
combination of prescribing data and disease codes. Validation 
suggests that completeness based on these criteria is ≥95%, 
although date of diagnosis of diabetes may be unreliable and 
there may be overestimation of the number of people with 
diabetes from glucose measurement alone.15
Some studies use coding of diabetes in hospital records to 
identify people with diabetes (for example)16 and the com-
pleteness of this approach can be expected to vary depending 
on choice of codes, outcome of interest and hospital.12 When 
using International Classification of Disease codes it is 
important to be aware of changes in coding rules between 
different revisions. For example there were important 
changes between the 9th and 10th revisions in Rule 3, which 
allows a condition originally identified as contributing to 
death to be assigned as the underlying cause of death if it is a 
direct consequence of the condition originally identified as 
the underlying cause.17 For example, under this rule when 
the underlying cause was recorded as nephrotic syndrome it 
would be reassigned to diabetes if diabetes was mentioned 
anywhere else in the certificate. In Scotland and England this 
change took place in 2000 and the number of deaths attrib-
uted to diabetes increased by approximately 4% as a 
consequence.18
In New Zealand and Canada algorithms have been devel-
oped to combine data from several sources, building on the 
capture-recapture approach that has been used previously to 
create population based diabetes registers.19-22 A systematic 
review and meta-analysis of 6 studies which reported sensi-
tivity and specificity of 2 physician claims or 1 hospital dis-
charge abstract record within a 2-year period as a case 
definition of diabetes concluded that the definition missed up 
to 20% of cases of diabetes and falsely identified 2% of peo-
ple as having diabetes.23
Population based prescribing or dispensing databases can 
be used to identify people with drug treated diabetes as the 
majority of drugs used to treat diabetes, with the exception of 
metformin, are not used for other indications. For example, 
Norwegian prescribing data have been used to validate a 
pediatric diabetes register and to estimate the prevalence of 
diabetes,24 although these data do not cover people in nursing 
homes, hospitals or other institutions so are likely to under-
estimate prevalence. Identifying the first date of prescription 
can be used to identify incident diagnoses although this may 
not be an accurate proxy for the date of diagnosis of diabetes. 
Prescribing data can be challenging to use as consequence of 
different coding systems for drug classes, unclear informa-
tion about start and stop dates, the potential for patients not 
to fill prescriptions, and the fact that a reasonably large pro-
portion of people with type 2 diabetes in many populations 
are not prescribed drug treatment. In Scotland in 2009, for 
example, we estimated that approximately 18 % of the 
196 000 people over 39 years of age with a diagnosis of type 
2 diabetes did not fill a prescription for treatment of diabetes, 
either because it was not prescribed or because they did not 
collect the prescription (unpublished data). This proportion 
is likely to vary between populations.
Type and Duration of Diabetes
Many diabetes databases do not distinguish between type 1 
and type 2 diabetes and those that do may rely on inconsis-
tent approaches applied to defining type of diabetes used by 
different clinical staff, resulting in misclassification. The 
legacy of the previous nomenclature of insulin-dependent 
diabetes and non-insulin-dependent diabetes means that the 
most frequent misclassification is of people who receive 
insulin treatment for type 2 diabetes receiving a label of type 
1 diabetes. It is possible to develop algorithms using a vari-
ety of different sources of information including age at diag-
nosis of diabetes and treatment patterns to classify or validate 
type of diabetes.25 The QRESEARCH group defines type 1 
diabetes as age ≤35 years at diagnosis and evidence of treat-
ment with insulin, including devices. As date of diagnosis of 
diabetes may not be recorded reliably, the algorithms may 
use other information from prescribing, biochemical or reti-
nopathy screening records to validate date of diagnosis of 
diabetes.26 Duration of diabetes is an important variable for 
many analyses and the absence of reliable information on 
date of diagnosis from many databases limits their value for 
research.
Other Factors
The availability of valid data on potential confounding fac-
tors, effect modifiers and outcomes of interest also influ-
ences the value of databases for audit and research. Although 
assays for key parameters such as HbA1c, creatinine, and 
estimated glomerular filtration rate are expected to be stan-
dardized, there is still the potential for important differences 
over time and between laboratories and extensive investiga-
tion and data manipulation may be required to ensure that 
meaningful comparisons can be made. Each variable that is 
used is likely to require cleaning to remove implausible data. 
Further challenges arise from irregular recording of key vari-
ables and large amounts of missing data. Modern computing 
capacity mean that methods for handling missing data in 
very large databases are now feasible and the validity of 
using complete case analysis (that is a restricted sample size 
of people with complete data) can now be assessed.
Opportunities and Challenges Relating 
to Use of Large Databases for Research
The availability of diabetes databases for research has 
increased in recent years, partly following recognition of the 
value of registries for managing individual care and for 
improving equity of outcomes of care across populations. 
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The amount of time and effort required to set up such sys-
tems should not be underestimated and partly explains the 
limited number of population-based registers, particularly in 
less developed countries. It is also important to understand 
the value of secondary uses of the data for research purposes 
if local requirements for data governance can be met (as dis-
cussed further below). There will be further opportunities for 
using these data if comparability across countries can be 
improved. Harmonization of data set definitions allows 
cross-country comparisons and pooling of data to examine 
rare outcomes. However, harmonization requires extensive 
work; collaborative projects such as EUBIROD are support-
ing the development of new diabetes data sets so that col-
leagues can benefit from the years of work and experience in 
setting up such systems in Scotland and other countries.27
Once the challenges of ensuring that the data in diabetes 
databases are internally valid have been met, as described 
above, it becomes possible to consider the wider applica-
tion of the data for research, either from linkage to other 
databases, where available, or to make comparisons with 
the general population. For example, diabetes databases 
can be used to identify diabetes as an outcome as an effi-
cient way of conducting longer term follow-up of partici-
pants in trials28 or observational studies such as birth 
cohorts.29
There may be data governance and logistical issues to 
address before anonymous linkage of data is possible with-
out explicit individual consent from all people whose infor-
mation is included in a database. There are marked differences 
between countries in the perceived balance between the 
advantages of having population level data for use by health 
services and researchers and the need to protect confidential-
ity. Proposed new European legislation might mean that dis-
ease registers based on implied consent are no longer allowed 
in the future so that data only become available from selected 
populations. Clearly protecting patient confidentiality and 
informing people how information about them might be used 
is essential and when setting up a new disease register 
informed consent should be obtained from individuals where 
feasible.
In Scotland a linked database of acute hospital admis-
sions, cancer registrations, deaths and admissions to psychi-
atric hospitals is available30 and the use of a unique national 
patient identifier (the Community Health Index number) on 
records, including those in the diabetes database, allows 
linkage prior to deidentification for research purposes. 
Examples of how the linked database have been used are 
available from various studies of morbidity and mortal-
ity.26,31-34 It is also possible to link to other disease registers 
in Scotland, such as the renal register.35 Several of these stud-
ies have made comparisons with either the general popula-
tion or the whole population without diabetes although this 
approach is usually limited to the ability to adjust for con-
founding by age, sex and an area-based measure of socioeco-
nomic status. Swedish colleagues undertaking similar studies 
have made comparisons between people with diabetes and 
controls randomly selected from the general population who 
were matched by age, sex, and geographical area.36 The 
potential for ascertainment bias in studies of the association 
between diabetes and cancer, in which the diagnoses of both 
conditions occur within a similar time frame, either because 
of opportunistic testing or increased surveillance should be 
noted.37
Pharmaco-epidemiological studies are also possible 
with use of prescribing data and often require interna-
tional collaboration to provide sufficient data, particularly 
for new drugs, requiring development of methods to share 
aggregated data and avoid sharing of individual-level data 
across countries.38,39 Observational studies of drug expo-
sure are prone to time-related bias. Many studies describ-
ing apparent benefits of metformin on cancer incidence 
have demonstrated such bias resulting in exaggerated esti-
mates of the benefits of metformin compared to studies 
that have avoided such bias.40,41 A further potential for 
misleading findings arises from the potential for con-
founding by indication or channeling bias in which risk of 
the outcome influences choice of drug. Approaches to 
tackling this issue include use of propensity scores but it 
is important to be aware of the limitations of these 
approaches.42
Conclusions
Several well-established and validated diabetes databases 
exist that provide the basis for valuable and efficient primary 
and secondary uses when data governance and methodologi-
cal challenges have been addressed. Although setting up 
such databases takes a considerable amount of resources and 
time there are opportunities to learn from the experience of 
people responsible for existing databases.
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